Skip to main content
. Author manuscript; available in PMC: 2017 Oct 3.
Published in final edited form as: Leuk Res. 2016 Aug 12;49:108–112. doi: 10.1016/j.leukres.2016.08.006

Table 4.

Response to Dasatinib or Nilotinib After Progression or Lack of Response to Imatinib in Patients with BCR-ABL135INS

Dasatinib n=7 Nilotinib n=16
Maintained response 4
(1CMR, 2 MMR; 1PMR)
3
(1 CMR, 1MMR; 1 PMR)
Stopped 20 toxicity 3 7
Responded, then progressed 0 2
No response 0 0
Lost to follow up 0 2
Non-compliant 0 2

PMR: partial molecular response

MMR: major molecular response

CMR: complete molecular response